Concepts (286)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cues | 36 | 2022 | 654 | 3.430 |
Why?
|
| Smoking Cessation | 27 | 2021 | 1034 | 3.190 |
Why?
|
| Smoking | 25 | 2020 | 1452 | 2.410 |
Why?
|
| Tobacco Use Disorder | 15 | 2019 | 432 | 2.340 |
Why?
|
| Progesterone | 4 | 2022 | 115 | 1.960 |
Why?
|
| Craving | 11 | 2022 | 200 | 1.850 |
Why?
|
| Cocaine-Related Disorders | 20 | 2015 | 504 | 1.820 |
Why?
|
| Stress, Psychological | 15 | 2022 | 824 | 1.800 |
Why?
|
| Substance Withdrawal Syndrome | 12 | 2018 | 435 | 1.790 |
Why?
|
| Nicotinic Agonists | 7 | 2018 | 111 | 1.630 |
Why?
|
| Nicotine | 10 | 2018 | 350 | 1.540 |
Why?
|
| Substance-Related Disorders | 15 | 2019 | 1242 | 1.300 |
Why?
|
| Menstrual Cycle | 7 | 2022 | 64 | 1.180 |
Why?
|
| Stress Disorders, Post-Traumatic | 21 | 2022 | 1506 | 1.170 |
Why?
|
| Estradiol | 3 | 2020 | 176 | 1.150 |
Why?
|
| Adult | 77 | 2022 | 21403 | 1.030 |
Why?
|
| Smokers | 5 | 2022 | 200 | 0.980 |
Why?
|
| Cigarette Smoking | 3 | 2020 | 104 | 0.920 |
Why?
|
| Saliva | 3 | 2022 | 142 | 0.910 |
Why?
|
| Smoking Prevention | 8 | 2017 | 259 | 0.900 |
Why?
|
| Behavior, Addictive | 10 | 2020 | 317 | 0.880 |
Why?
|
| Female | 84 | 2022 | 38074 | 0.860 |
Why?
|
| Social Environment | 5 | 2020 | 182 | 0.850 |
Why?
|
| Motivation | 9 | 2018 | 561 | 0.850 |
Why?
|
| Varenicline | 5 | 2021 | 98 | 0.840 |
Why?
|
| Memory Consolidation | 2 | 2019 | 7 | 0.820 |
Why?
|
| Adolescent | 39 | 2022 | 8912 | 0.780 |
Why?
|
| Tobacco Products | 5 | 2020 | 234 | 0.780 |
Why?
|
| Luteal Phase | 5 | 2022 | 25 | 0.770 |
Why?
|
| Amphetamine-Related Disorders | 6 | 2012 | 92 | 0.750 |
Why?
|
| Tobacco Smoking | 2 | 2020 | 41 | 0.740 |
Why?
|
| Young Adult | 26 | 2022 | 5717 | 0.720 |
Why?
|
| Humans | 95 | 2022 | 68618 | 0.710 |
Why?
|
| Male | 74 | 2022 | 37321 | 0.700 |
Why?
|
| Alcoholism | 14 | 2022 | 1109 | 0.700 |
Why?
|
| Health Behavior | 4 | 2018 | 458 | 0.690 |
Why?
|
| Adaptation, Psychological | 6 | 2018 | 447 | 0.680 |
Why?
|
| Affect | 7 | 2015 | 218 | 0.680 |
Why?
|
| Sex Characteristics | 3 | 2019 | 295 | 0.680 |
Why?
|
| Anxiety Disorders | 2 | 2019 | 426 | 0.660 |
Why?
|
| Oxytocin | 2 | 2020 | 124 | 0.650 |
Why?
|
| Hydrocortisone | 9 | 2022 | 291 | 0.610 |
Why?
|
| Middle Aged | 41 | 2022 | 21147 | 0.600 |
Why?
|
| Follicular Phase | 4 | 2015 | 15 | 0.560 |
Why?
|
| Alcohol Drinking | 6 | 2022 | 805 | 0.530 |
Why?
|
| Gender Identity | 2 | 2015 | 47 | 0.530 |
Why?
|
| Quinoxalines | 2 | 2015 | 78 | 0.510 |
Why?
|
| Benzazepines | 2 | 2015 | 104 | 0.510 |
Why?
|
| Learning | 1 | 2017 | 186 | 0.500 |
Why?
|
| Crime Victims | 3 | 2008 | 286 | 0.490 |
Why?
|
| Sex Factors | 11 | 2020 | 1266 | 0.430 |
Why?
|
| Propranolol | 1 | 2013 | 103 | 0.430 |
Why?
|
| Memory | 2 | 2018 | 214 | 0.420 |
Why?
|
| Cycloserine | 4 | 2015 | 30 | 0.410 |
Why?
|
| Surveys and Questionnaires | 14 | 2015 | 2800 | 0.400 |
Why?
|
| Affective Symptoms | 1 | 2012 | 50 | 0.400 |
Why?
|
| Obsessive Behavior | 1 | 2011 | 6 | 0.400 |
Why?
|
| Extinction, Psychological | 5 | 2017 | 240 | 0.390 |
Why?
|
| Research Design | 3 | 2016 | 729 | 0.370 |
Why?
|
| Spinal Cord Injuries | 2 | 2015 | 551 | 0.370 |
Why?
|
| Cocaine | 5 | 2022 | 555 | 0.350 |
Why?
|
| Stress, Physiological | 4 | 2020 | 215 | 0.350 |
Why?
|
| Crack Cocaine | 2 | 2006 | 20 | 0.340 |
Why?
|
| Psychometrics | 6 | 2009 | 514 | 0.330 |
Why?
|
| Double-Blind Method | 9 | 2019 | 1738 | 0.320 |
Why?
|
| Reflex, Startle | 2 | 2013 | 39 | 0.310 |
Why?
|
| Recurrence | 4 | 2019 | 948 | 0.310 |
Why?
|
| Implosive Therapy | 2 | 2022 | 171 | 0.290 |
Why?
|
| Arousal | 5 | 2015 | 168 | 0.290 |
Why?
|
| Adrenocorticotropic Hormone | 7 | 2011 | 106 | 0.290 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 5 | 2013 | 257 | 0.260 |
Why?
|
| Exercise | 2 | 2022 | 658 | 0.250 |
Why?
|
| Zygapophyseal Joint | 1 | 2004 | 5 | 0.250 |
Why?
|
| Ultrasonics | 1 | 2004 | 17 | 0.250 |
Why?
|
| Family Relations | 1 | 2005 | 47 | 0.250 |
Why?
|
| Fear | 2 | 2019 | 239 | 0.240 |
Why?
|
| Body Temperature | 1 | 2004 | 116 | 0.240 |
Why?
|
| Behavior Therapy | 3 | 2018 | 297 | 0.240 |
Why?
|
| Hot Temperature | 1 | 2004 | 152 | 0.230 |
Why?
|
| Depressive Disorder | 1 | 2008 | 621 | 0.230 |
Why?
|
| Depression | 2 | 2022 | 943 | 0.230 |
Why?
|
| Cold Temperature | 4 | 2006 | 90 | 0.220 |
Why?
|
| Women's Health | 3 | 2015 | 148 | 0.220 |
Why?
|
| Administration, Intranasal | 2 | 2020 | 88 | 0.220 |
Why?
|
| Follow-Up Studies | 5 | 2019 | 3259 | 0.210 |
Why?
|
| Neurofeedback | 2 | 2013 | 34 | 0.210 |
Why?
|
| Prospective Studies | 4 | 2020 | 3705 | 0.210 |
Why?
|
| Hallucinogens | 1 | 2022 | 14 | 0.210 |
Why?
|
| Heart Rate | 8 | 2019 | 568 | 0.210 |
Why?
|
| Computer Simulation | 1 | 2006 | 706 | 0.210 |
Why?
|
| Analysis of Variance | 7 | 2013 | 1040 | 0.200 |
Why?
|
| Psychiatric Status Rating Scales | 10 | 2010 | 782 | 0.190 |
Why?
|
| Research | 2 | 2019 | 214 | 0.190 |
Why?
|
| Cannabis | 1 | 2022 | 115 | 0.190 |
Why?
|
| Counseling | 3 | 2019 | 280 | 0.180 |
Why?
|
| Treatment Outcome | 9 | 2019 | 7029 | 0.180 |
Why?
|
| Severity of Illness Index | 8 | 2010 | 1851 | 0.180 |
Why?
|
| Sex Offenses | 1 | 2022 | 170 | 0.180 |
Why?
|
| Comorbidity | 11 | 2007 | 1426 | 0.170 |
Why?
|
| Smoking Devices | 1 | 2019 | 6 | 0.170 |
Why?
|
| Methamphetamine | 3 | 2010 | 132 | 0.170 |
Why?
|
| Impulsive Behavior | 2 | 2015 | 85 | 0.170 |
Why?
|
| Hypothalamo-Hypophyseal System | 6 | 2022 | 150 | 0.160 |
Why?
|
| Pituitary-Adrenal System | 6 | 2022 | 138 | 0.160 |
Why?
|
| Ganglionic Stimulants | 2 | 2009 | 15 | 0.160 |
Why?
|
| Cognition Disorders | 2 | 2012 | 342 | 0.160 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2021 | 180 | 0.160 |
Why?
|
| Life Change Events | 4 | 2008 | 223 | 0.160 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2019 | 124 | 0.150 |
Why?
|
| Reproducibility of Results | 6 | 2019 | 2077 | 0.150 |
Why?
|
| Exercise Therapy | 1 | 2019 | 183 | 0.150 |
Why?
|
| Cognition | 2 | 2011 | 513 | 0.150 |
Why?
|
| Cross-Sectional Studies | 4 | 2014 | 2279 | 0.140 |
Why?
|
| Chi-Square Distribution | 2 | 2013 | 546 | 0.140 |
Why?
|
| Mental Recall | 1 | 2017 | 72 | 0.140 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2018 | 189 | 0.140 |
Why?
|
| Behavioral Research | 1 | 2016 | 10 | 0.130 |
Why?
|
| Personality Inventory | 2 | 2012 | 197 | 0.130 |
Why?
|
| Ethanol | 1 | 2002 | 893 | 0.130 |
Why?
|
| Time Factors | 5 | 2019 | 4655 | 0.130 |
Why?
|
| Logistic Models | 3 | 2015 | 1420 | 0.130 |
Why?
|
| Transdermal Patch | 1 | 2015 | 21 | 0.130 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2018 | 468 | 0.120 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2013 | 73 | 0.110 |
Why?
|
| Substance Abuse Treatment Centers | 4 | 2011 | 71 | 0.110 |
Why?
|
| Acetylcysteine | 2 | 2007 | 296 | 0.110 |
Why?
|
| Feasibility Studies | 3 | 2019 | 652 | 0.110 |
Why?
|
| Antimetabolites | 1 | 2013 | 17 | 0.110 |
Why?
|
| Injury Severity Score | 1 | 2013 | 204 | 0.110 |
Why?
|
| Pilot Projects | 5 | 2021 | 1342 | 0.110 |
Why?
|
| Family Health | 1 | 2013 | 83 | 0.110 |
Why?
|
| Southeastern United States | 1 | 2013 | 281 | 0.110 |
Why?
|
| Brain | 2 | 2013 | 2176 | 0.100 |
Why?
|
| Individuality | 1 | 2012 | 44 | 0.100 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2012 | 52 | 0.100 |
Why?
|
| Ovary | 1 | 2012 | 99 | 0.100 |
Why?
|
| Valproic Acid | 1 | 2012 | 93 | 0.100 |
Why?
|
| Risk Factors | 4 | 2013 | 5731 | 0.100 |
Why?
|
| Gyrus Cinguli | 1 | 2012 | 113 | 0.100 |
Why?
|
| Corticotropin-Releasing Hormone | 2 | 2009 | 79 | 0.100 |
Why?
|
| Prevalence | 5 | 2015 | 1619 | 0.090 |
Why?
|
| Telephone | 2 | 2010 | 160 | 0.090 |
Why?
|
| Aged | 11 | 2018 | 14862 | 0.090 |
Why?
|
| Association Learning | 1 | 2010 | 36 | 0.090 |
Why?
|
| Pain | 1 | 2013 | 472 | 0.090 |
Why?
|
| Psychomotor Performance | 2 | 2012 | 213 | 0.080 |
Why?
|
| Child Abuse | 4 | 2006 | 186 | 0.080 |
Why?
|
| Models, Psychological | 2 | 2009 | 180 | 0.080 |
Why?
|
| Internal-External Control | 1 | 2009 | 60 | 0.080 |
Why?
|
| Galvanic Skin Response | 4 | 2010 | 67 | 0.080 |
Why?
|
| Retrospective Studies | 5 | 2020 | 7277 | 0.080 |
Why?
|
| Health Personnel | 1 | 2011 | 286 | 0.080 |
Why?
|
| Avoidance Learning | 1 | 2009 | 58 | 0.080 |
Why?
|
| Patient Selection | 2 | 2010 | 592 | 0.080 |
Why?
|
| United States | 2 | 2020 | 7367 | 0.080 |
Why?
|
| Attitude of Health Personnel | 1 | 2011 | 442 | 0.080 |
Why?
|
| Interviews as Topic | 1 | 2009 | 392 | 0.080 |
Why?
|
| Rural Population | 1 | 2011 | 398 | 0.080 |
Why?
|
| Social Behavior | 1 | 2009 | 164 | 0.080 |
Why?
|
| Marijuana Abuse | 1 | 2011 | 251 | 0.080 |
Why?
|
| Psychology, Child | 1 | 2007 | 28 | 0.080 |
Why?
|
| Central Nervous System Stimulants | 2 | 2010 | 221 | 0.070 |
Why?
|
| Age of Onset | 1 | 2007 | 188 | 0.070 |
Why?
|
| Drug-Seeking Behavior | 1 | 2010 | 213 | 0.070 |
Why?
|
| Crime | 2 | 1997 | 53 | 0.070 |
Why?
|
| Predictive Value of Tests | 5 | 2011 | 1465 | 0.070 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 2 | 2003 | 151 | 0.070 |
Why?
|
| Touch | 1 | 2006 | 25 | 0.070 |
Why?
|
| Photic Stimulation | 3 | 2012 | 229 | 0.070 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2009 | 266 | 0.070 |
Why?
|
| Prefrontal Cortex | 1 | 2012 | 640 | 0.070 |
Why?
|
| Neurosecretory Systems | 2 | 2020 | 21 | 0.070 |
Why?
|
| Token Economy | 1 | 2005 | 12 | 0.070 |
Why?
|
| Tobacco | 1 | 2006 | 161 | 0.060 |
Why?
|
| Interview, Psychological | 3 | 2003 | 113 | 0.060 |
Why?
|
| Narcotic Antagonists | 1 | 2006 | 184 | 0.060 |
Why?
|
| Ultrasonic Therapy | 1 | 2004 | 19 | 0.060 |
Why?
|
| Naltrexone | 1 | 2006 | 195 | 0.060 |
Why?
|
| Lumbar Vertebrae | 1 | 2004 | 112 | 0.060 |
Why?
|
| Spouse Abuse | 1 | 2003 | 40 | 0.060 |
Why?
|
| South Carolina | 4 | 2013 | 2752 | 0.060 |
Why?
|
| Ambulatory Care | 1 | 2005 | 340 | 0.050 |
Why?
|
| Psychotherapy | 1 | 2005 | 253 | 0.050 |
Why?
|
| Drive | 1 | 2002 | 4 | 0.050 |
Why?
|
| Cannabinoid Receptor Agonists | 1 | 2022 | 20 | 0.050 |
Why?
|
| Blood Pressure | 1 | 2008 | 1451 | 0.050 |
Why?
|
| Neuropsychological Tests | 3 | 2012 | 517 | 0.050 |
Why?
|
| Environment | 1 | 2022 | 115 | 0.050 |
Why?
|
| Regression Analysis | 1 | 2003 | 737 | 0.050 |
Why?
|
| Antidepressive Agents | 1 | 2022 | 216 | 0.050 |
Why?
|
| Reward | 1 | 2003 | 201 | 0.050 |
Why?
|
| Administration, Cutaneous | 2 | 2013 | 56 | 0.050 |
Why?
|
| Oxygen | 2 | 2013 | 386 | 0.050 |
Why?
|
| Neuroendocrine Cells | 1 | 2020 | 8 | 0.050 |
Why?
|
| Data Interpretation, Statistical | 2 | 2013 | 329 | 0.050 |
Why?
|
| Mental Health | 1 | 2022 | 278 | 0.040 |
Why?
|
| Salivation | 1 | 1999 | 7 | 0.040 |
Why?
|
| Placebos | 2 | 2012 | 195 | 0.040 |
Why?
|
| Physical Exertion | 1 | 2019 | 75 | 0.040 |
Why?
|
| Hormone Antagonists | 1 | 2018 | 6 | 0.040 |
Why?
|
| Self Disclosure | 1 | 1998 | 55 | 0.040 |
Why?
|
| Personal Satisfaction | 1 | 2019 | 123 | 0.040 |
Why?
|
| Socioeconomic Factors | 2 | 2013 | 955 | 0.040 |
Why?
|
| Perception | 1 | 2019 | 189 | 0.040 |
Why?
|
| Day Care, Medical | 1 | 1997 | 18 | 0.040 |
Why?
|
| Psychomotor Agitation | 1 | 1997 | 63 | 0.040 |
Why?
|
| Self Report | 1 | 2019 | 371 | 0.040 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 1999 | 189 | 0.040 |
Why?
|
| Ecological Momentary Assessment | 1 | 2016 | 16 | 0.040 |
Why?
|
| Patient Compliance | 1 | 2019 | 402 | 0.030 |
Why?
|
| Neuronal Plasticity | 1 | 2019 | 274 | 0.030 |
Why?
|
| Combined Modality Therapy | 2 | 2015 | 951 | 0.030 |
Why?
|
| Luteinizing Hormone | 1 | 2016 | 31 | 0.030 |
Why?
|
| Continuity of Patient Care | 1 | 1997 | 170 | 0.030 |
Why?
|
| Bias | 1 | 1997 | 148 | 0.030 |
Why?
|
| Cross-Over Studies | 2 | 2007 | 260 | 0.030 |
Why?
|
| Dementia | 1 | 1997 | 158 | 0.030 |
Why?
|
| Community Health Planning | 1 | 2015 | 19 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 1054 | 0.030 |
Why?
|
| Child | 4 | 2000 | 6405 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2015 | 216 | 0.030 |
Why?
|
| Educational Status | 2 | 2011 | 273 | 0.030 |
Why?
|
| Length of Stay | 1 | 1997 | 780 | 0.030 |
Why?
|
| Child Abuse, Sexual | 1 | 1995 | 150 | 0.030 |
Why?
|
| Biomarkers | 1 | 2019 | 1593 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2013 | 2223 | 0.030 |
Why?
|
| Conditioning, Eyelid | 1 | 2013 | 2 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2013 | 215 | 0.030 |
Why?
|
| Carbon Monoxide | 1 | 2013 | 58 | 0.030 |
Why?
|
| Electromyography | 1 | 2013 | 184 | 0.030 |
Why?
|
| Acoustic Stimulation | 1 | 2013 | 206 | 0.030 |
Why?
|
| Volition | 1 | 2012 | 16 | 0.030 |
Why?
|
| Mass Screening | 1 | 1998 | 843 | 0.030 |
Why?
|
| Probability | 2 | 2007 | 245 | 0.030 |
Why?
|
| Disasters | 1 | 1994 | 204 | 0.020 |
Why?
|
| Age Factors | 2 | 2007 | 1864 | 0.020 |
Why?
|
| Functional Neuroimaging | 1 | 2012 | 82 | 0.020 |
Why?
|
| Reaction Time | 1 | 2012 | 170 | 0.020 |
Why?
|
| Psychological Tests | 1 | 2011 | 96 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 2011 | 193 | 0.020 |
Why?
|
| Family | 1 | 2013 | 293 | 0.020 |
Why?
|
| Motor Skills | 1 | 2011 | 88 | 0.020 |
Why?
|
| Demography | 1 | 2011 | 279 | 0.020 |
Why?
|
| Linear Models | 1 | 2012 | 521 | 0.020 |
Why?
|
| Data Collection | 1 | 2011 | 420 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2013 | 689 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2015 | 2358 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 536 | 0.020 |
Why?
|
| Control Groups | 1 | 2007 | 10 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2009 | 714 | 0.020 |
Why?
|
| Immersion | 1 | 2006 | 10 | 0.020 |
Why?
|
| Pituitary Gland | 1 | 2006 | 29 | 0.020 |
Why?
|
| Adrenal Glands | 1 | 2006 | 46 | 0.020 |
Why?
|
| Thermosensing | 1 | 2006 | 10 | 0.020 |
Why?
|
| Visual Perception | 1 | 2007 | 124 | 0.020 |
Why?
|
| Hypothalamus | 1 | 2006 | 78 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2007 | 291 | 0.020 |
Why?
|
| Neurologic Examination | 1 | 2006 | 107 | 0.020 |
Why?
|
| Substance Abuse Detection | 1 | 2005 | 66 | 0.020 |
Why?
|
| Survivors | 1 | 2007 | 256 | 0.020 |
Why?
|
| Circadian Rhythm | 1 | 2006 | 218 | 0.020 |
Why?
|
| Reference Values | 1 | 2006 | 579 | 0.020 |
Why?
|
| Sensitivity and Specificity | 2 | 1998 | 1753 | 0.010 |
Why?
|
| Intelligence Tests | 1 | 2003 | 32 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2003 | 274 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2006 | 1553 | 0.010 |
Why?
|
| Disruptive, Impulse Control, and Conduct Disorders | 1 | 2002 | 19 | 0.010 |
Why?
|
| Temperance | 1 | 2002 | 41 | 0.010 |
Why?
|
| Imagination | 1 | 2002 | 38 | 0.010 |
Why?
|
| Hospitalization | 1 | 2007 | 978 | 0.010 |
Why?
|
| Animals | 1 | 2018 | 20881 | 0.010 |
Why?
|
| Water | 1 | 1999 | 230 | 0.010 |
Why?
|
| Psychotherapy, Brief | 1 | 1997 | 30 | 0.010 |
Why?
|
| Discriminant Analysis | 1 | 1997 | 36 | 0.010 |
Why?
|
| Aggression | 1 | 1997 | 98 | 0.010 |
Why?
|
| Activities of Daily Living | 1 | 1997 | 319 | 0.010 |
Why?
|
| Sampling Studies | 1 | 1995 | 80 | 0.010 |
Why?
|
| Patient Care Team | 1 | 1997 | 311 | 0.010 |
Why?
|
| Personality Assessment | 1 | 1995 | 71 | 0.010 |
Why?
|
| Causality | 1 | 1995 | 82 | 0.010 |
Why?
|
| Mental Disorders | 1 | 2000 | 659 | 0.010 |
Why?
|
| Marital Status | 1 | 1994 | 65 | 0.010 |
Why?
|
| California | 1 | 1994 | 99 | 0.010 |
Why?
|
| Income | 1 | 1994 | 167 | 0.010 |
Why?
|
| Incidence | 1 | 1995 | 1603 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 1997 | 4848 | 0.000 |
Why?
|